drugset
Drugs / HUMSCs
last change Apr 2026 re-read 3 minutes ago

HUMSCs

also known as human umbilical cord mesenchymal stem cells

Cell therapy

Developed for
intracerebral hemorrhage
Investigated by
First Affiliated Hospital of Fujian Medical University · Jinhua Hospital, School of Medicine, Zhejiang University · Second Affiliated Hospital, School of Medicine, Zhejiang University · Taizhou Hospital · The First Affiliated Hospital of Xinxiang Medical College · The First Affiliated Hospital, University of Science and Technology of China
+1 more · Zhejiang University

Trials 2

today NCT07530003 · Ph 1/2 NCT04074408 · Ph 2
20212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT07530003 Apr 2026 → Dec 2027 expected — The First Affiliated Hospital of Xinxiang Medical College Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT04074408 May 2020 → Nov 2022 intracerebral hemorrhage Second Affiliated Hospital, School of Medicine, Zhejiang University Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as HUMSCs ClinicalTrials.gov intervention name — accepted as the source's own label NCT07530003 ↗
1

NCT04074408 ↗
Known as human umbilical cord mesenchymal stem cells “human umbilical cord mesenchymal stem cells (HUMSCs)” NCT07530003 ↗
1

“human umbilical cord mesenchymal stem cells (hUMSCs)” NCT04074408 ↗
Modality Cell therapy “human umbilical cord mesenchymal stem cells (hUMSCs)” NCT04074408 ↗
Route Other “single intracavitary infusion 1 day after stereotactic aspiration surgery” NCT04074408 ↗